VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (8800)	6/6/2001 12:37:41 AM
From: Miljenko Zuanic	Read Replies (1) of 9719

V1, Several months ago I called CELG risky bet @30, based on T slow progress with MM and concern about colon cancer trial. Recent news on collaborative colon cancer trial with PNU irinotecan did intrigue my curiosity. Mechanism by which T suppress Irinotecan toxicity and will this reduce its efficacy? Specially after two lead colon cancer trial were halted. Hope that CELG will be able to take advantage of this development (in addition that T is in combination with SU5416 in PI/II colon cancer trial, and that 5416 and Irinoitecan may become standard therapy). Also, some positive early data from Signal work are surfacing. Miljenko Disclaimer: Without CELG position

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next